What's new in the treatment of advanced prostate cancer?
- 31 January 2003
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (2) , 136-146
- https://doi.org/10.1016/s0959-8049(02)00665-2
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Low Dose Ketoconazole With Replacement Doses of Hydrocortisone in Patients With Progressive Androgen Independent Prostate CancerJournal of Urology, 2002
- A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate CancerJournal of Urology, 2002
- A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerUrology, 2001
- Systemic treatment and new developments in advanced prostate cancerEuropean Journal Of Cancer, 2001
- Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patientsEuropean Journal Of Cancer, 2001
- Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model systemBritish Journal of Cancer, 1999
- Antiandrogens in Prostate CancerInvestigational New Drugs, 1999
- Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide WithdrawalJournal of Urology, 1997
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Editorial: Hormone refractory metastatic prostate cancerAnnals of Oncology, 1992